About
David J. Hellerstein, MD, is affiliated with Columbia University Vagelos College of Physicians and Surgeons and the New York State Psychiatric Institute. His publications from 1999 to 2025 focus on major depressive disorder, including treatment-resistant depression, and explore topics such as psychedelic therapies, antidepressant medications, psychotherapy, and primary care approaches. His work includes clinical trials and observational studies on drugs like psilocybin, duloxetine, venlafaxine, and sertraline, as well as investigations into psychological support in psychedelic therapy.
